Darolutamide Extends Survival in Metastatic Prostate Cancer - NCI

Adding darolutamide (Nubeqa) to ADT and docetaxel improves survival in hormone-sensitive metastatic prostate cancer, results from the ARASENS trial show.

Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate

Darolutamide: New Standard of Care in Nonmetastatic CRPC?

FDA Expands Nubeqa Indications for Prostate Cancer - GoodRx

Testosterone suppression plus enzalutamide versus testosterone

ARASENS: Darolutamide Plus ADT and Docetaxel May Become New

Current Oncology, Free Full-Text

Androgen receptor pathway inhibitors, prostate cancer, and older

Nubeqa Delays Prostate Cancer Progression in Resistant Prostate

The treatment landscape of metastatic prostate cancer - ScienceDirect

Darolutamide and Survival in Metastatic, Hormone-Sensitive